Primary Indication: PKU Patients
Sapropterin (Kuvan) was clinically studied in patients with phenylketonuria (PKU), a genetic disorder causing high phenylalanine (Phe) levels. Key trials focused on children and adults with moderate to severe hyperphenylalaninemia due to tetrahydrobiopterin (BH4)-responsive PKU.
- Age 4 years and older: Pivotal trials enrolled 242 patients aged 4+ with baseline blood Phe >10 mg/dL. Responders (30% Phe reduction) included those on Phe-restricted diets.[1]
- Children 0-4 years: Separate studies tested infants and toddlers (starting at 1 month) to assess early intervention for BH4-responsive PKU, showing Phe reductions in responders.[2]
Hyperphenylalaninemia Without PKU
Smaller trials included patients with hyperphenylalaninemia not due to PKU (e.g., BH4 synthesis deficiencies), confirming sapropterin's role in reducing Phe across BH4-responsive forms.[1]
Ongoing and Expanded Studies
Post-approval research targeted pregnant women with PKU (PKU-MOMs trial) to evaluate maternal Phe control and fetal outcomes, plus long-term data in pediatric extensions up to 6+ years.[3]
Sources
[1]: FDA Label for Kuvan
[2]: BioMarin Clinical Trials Summary
[3]: DrugPatentWatch.com - Sapropterin Clinical Overview